The Latest

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier […]
November 4, 2021

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, with a virtual fireside chat at 4:00 pm CET/10:00 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.nyxoah.com/

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment

Total
0
Shares
Share
Tweet
Previous Article

PSI Talent Management Acquires Propel International

Next Article

Syria, Russia cooperate on combating terrorism, Russian Ambassador says

Related Posts

HMC FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Honda Motor Co., Ltd. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – HMC

NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depository Shares (“ADSs”) of Honda Motor Co., Ltd. (NYSE: HMC) between June 20, 2018 and September 28, 2022, both dates inclusive (the “Class Period”) of the important April 3, 2023 lead plaintiff deadline. SO WHAT: If […]

CCTV+: A Piece of Song Porcelain from Baishe Kiln

BEIJING, Nov. 7, 2022 /PRNewswire/ — “When the rain ceases and the clouds roll out, the color of the sky is just the perfect color for the bluish-white porcelain.” This is how the ancient Chinese described the bluish-white porcelain of the Song Dynasty. Carrying a bluish-white color with a delicate appearance, it shines over one […]

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Voyager Digital Holdings Investors to Secure Counsel Before Important Deadline in Securities Class Action – VGX

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Voyager Earn Accounts and VGX tokens (“Voyager Investment Products”) between January 1, 2020 and November 9, 2022, inclusive (the “Class Period”), against Stephen Ehrlich, Gerard […]